Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, Powles T, Szabados B. Renal cell carcinoma. Lancet. 2024;404(10451):476–91. https://doi.org/10.1016/S0140-6736(24)00917-6.

Article  CAS  PubMed  Google Scholar 

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. https://doi.org/10.1038/nrdp.2017.9.

Article  PubMed  PubMed Central  Google Scholar 

Verbiest A, Couchy G, Job S, Caruana L, Lerut E, Oyen R, de Reynies A, Tosco L, Joniau S, Van Poppel H, et al. Molecular subtypes of clear-cell renal cell carcinoma are prognostic for outcome after complete metastasectomy. Eur Urol. 2018;74(4):474–80. https://doi.org/10.1016/j.eururo.2018.01.042.

Article  CAS  PubMed  Google Scholar 

Geynisman DM, Plimack ER. Systemic therapy for advanced non-clear-cell renal cell carcinoma: slow but definite progress. Eur Urol. 2021;80(2):171–3. https://doi.org/10.1016/j.eururo.2021.04.031.

Article  PubMed  Google Scholar 

Neuzillet Y, Tillou X, Mathieu R, Long JA, Gigante M, Paparel P, Poissonnier L, Baumert H, Escudier B, Lang H, et al. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol. 2011;60(2):366–73. https://doi.org/10.1016/j.eururo.2011.02.035.

Article  PubMed  Google Scholar 

Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011;60(4):644–61. https://doi.org/10.1016/j.eururo.2011.06.041.

Article  PubMed  Google Scholar 

Van Poppel H, Becker F, Cadeddu JA, Gill IS, Janetschek G, Jewett MA, Laguna MP, Marberger M, Montorsi F, Polascik TJ, et al. Treatment of localised renal cell carcinoma. Eur Urol. 2011;60(4):662–72. https://doi.org/10.1016/j.eururo.2011.06.040.

Article  PubMed  Google Scholar 

Wang J, Yin X, He W, Xue W, Zhang J, Huang Y. SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis. Acta Pharm Sin B. 2021;11(2):406–19. https://doi.org/10.1016/j.apsb.2020.09.015.

Article  CAS  PubMed  Google Scholar 

Stewart GD, O’Mahony FC, Powles T, Riddick AC, Harrison DJ, Faratian D. What can molecular pathology contribute to the management of renal cell carcinoma? Nat Rev Urol. 2011;8(5):255–65. https://doi.org/10.1038/nrurol.2011.43.

Article  CAS  PubMed  Google Scholar 

Yang Q, Zhuo Z, Qiu X, Luo R, Guo K, Wu H, Jiang R, Li J, Lian Q, Chen P, et al. Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma. J Transl Med. 2024;22(1):122. https://doi.org/10.1186/s12967-024-04926-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jansen S, Gosens R, Wieland T, Schmidt M. Paving the Rho in cancer metastasis: Rho GTPases and beyond. Pharmacol Ther. 2018;183:1–21. https://doi.org/10.1016/j.pharmthera.2017.09.002.

Article  CAS  PubMed  Google Scholar 

Shen C, Kaelin WG Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013;23(1):18–25. https://doi.org/10.1016/j.semcancer.2012.06.001.

Article  CAS  PubMed  Google Scholar 

Akhtar M, Al-Bozom IA, Al Hussain T. Molecular and metabolic basis of clear cell carcinoma of the kidney. Adv Anat Pathol. 2018;25(3):189–96. https://doi.org/10.1097/PAP.0000000000000185.

Article  CAS  PubMed  Google Scholar 

Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909–18. https://doi.org/10.1038/s41591-020-0839-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye Y, Zeng S, Hu X. Unveiling the hidden role of disulfidptosis in kidney renal clear cell carcinoma: a prognostic signature for personalized treatment. Apoptosis. 2024;29(5–6):693–708. https://doi.org/10.1007/s10495-023-01933-2.

Article  CAS  PubMed  Google Scholar 

Sun Z, Tao W, Guo X, Jing C, Zhang M, Wang Z, Kong F, Suo N, Jiang S, Wang H. Construction of a lactate-related prognostic signature for predicting prognosis, tumor microenvironment, and immune response in kidney renal clear cell carcinoma. Front Immunol. 2022;13: 818984. https://doi.org/10.3389/fimmu.2022.818984.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Pan Y, Jin X, Chen G. Identification of a Four hypoxia-associated long non-coding RNA signature and establishment of a nomogram predicting prognosis of clear cell renal cell carcinoma. Front Oncol. 2021;11: 713346. https://doi.org/10.3389/fonc.2021.713346.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luo G, Wang L, Zheng Z, Gao B, Lei C. Cuproptosis-Related Ferroptosis genes for Predicting Prognosis in kidney renal clear cell carcinoma. Eur J Med Res. 2023;28(1):176. https://doi.org/10.1186/s40001-023-01137-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Y, Li L, Yang W, Zhang K, Zhang Z, Yu C, Qiu J, Cai L, Gong Y, Zhang Z, et al. TRAF2 promotes M2-polarized tumor-associated macrophage infiltration, angiogenesis and cancer progression by inhibiting autophagy in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2023;42(1):159. https://doi.org/10.1186/s13046-023-02742-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, Barretina J, Gelfand ET, Bielski CM, Li H, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569(7757):503–8. https://doi.org/10.1038/s41586-019-1186-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O’Brien T, Martincorena I, Tarpey P, Angelopoulos N, Yates LR, et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell. 2018;173(3):611–23. https://doi.org/10.1016/j.cell.2018.02.020.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832–41. https://doi.org/10.1200/JCO.2005.05.179.

Article  PubMed  Google Scholar 

Perez-Valderrama B, Arranz Arija JA, Rodriguez Sanchez A, Pinto Marin A, Borrega Garcia P, Castellano Gaunas DE, Rubio Romero G, Maximiano Alonso C, Villa Guzman JC, Puertas Alvarez JL, et al. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study. Ann Oncol. 2016;27(4):706–11. https://doi.org/10.1093/annonc/mdv601.

Article  CAS  PubMed  Google Scholar 

Boguslawska J, Kedzierska H, Poplawski P, Rybicka B, Tanski Z, Piekielko-Witkowska A. Expression of genes involved in cellular adhesion and extracellular matrix remodeling correlates with poor survival of patients with renal cancer. J Urol. 2016;195(6):1892–902. https://doi.org/10.1016/j.juro.2015.11.050.

Article  CAS  PubMed  Google Scholar 

Hoff PM, Machado KK. Role of angiogenesis in the pathogenesis of cancer. Cancer Treat Rev. 2012;38(7):825–33. https://doi.org/10.1016/j.ctrv.2012.04.006.

Article  CAS  PubMed  Google Scholar 

Morgado M, Cairrao E, Santos-Silva AJ, Verde I. Cyclic nucleotide-dependent relaxation pathways in vascular smooth muscle. Cell Mol Life Sci. 2012;69(2):247–66. https://doi.org/10.1007/s00018-011-0815-2.

Article  CAS